Liesel FitzGerald

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5689473/publications.pdf

Version: 2024-02-01

31 papers	2,352 citations	567281 15 h-index	434195 31 g-index
32 all docs	32 docs citations	32 times ranked	5194 citing authors

#	Article	IF	Citations
1	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
2	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
3	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	21.4	377
4	Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer, 2008, 8, 230.	2.6	145
5	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	6.3	129
6	Cumulative Burden of Colorectal Cancerâ€“Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	1.3	110
7	Genetic Variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1928-1936.	2.5	68
8	Genome-wide Association Study Identifies a Genetic Variant Associated with Risk for More Aggressive Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1196-1203.	2.5	48
9	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology, 2021, 4, 570-579.	5.4	38
10	Effect of MELANOTANÂ®, [Nle4, D-Phe7]-Î±-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides, 2006, 27, 388-394.	2.4	35
11	Germline Missense Variants in the BTNL2 Gene Are Associated with Prostate Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1520-1528.	2.5	35
12	Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer and Prostatic Diseases, 2009, 12, 192-197.	3.9	28
13	Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. European Urology, 2021, 79, 353-361.	1.9	28
14	Investigation of the Relationship Between Prostate Cancer andMSMBandNCOA4Genetic Variants and Protein Expression. Human Mutation, 2013, 34, 149-156.	2.5	26
15	Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Human Molecular Genetics, 2009, 18, 1839-1848.	2.9	25
16	Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation. Genes, 2019, 10, 599.	2.4	17
17	Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand. JAMA Network Open, 2021, 4, e2129647.	5.9	13
18	Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes. Oncotarget, 2017, 8, 1495-1507.	1.8	11

#	Article	IF	Citations
19	A rare variant in <scp>EZH2</scp> is associated with prostate cancer risk. International Journal of Cancer, 2021, 149, 1089-1099.	5.1	9
20	Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours. Scientific Reports, 2017, 7, 17778.	3.3	8
21	Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer and Prostatic Diseases, 2018, 21, 228-237.	3.9	8
22	A fourâ€gene transcript score to predict metastaticâ€lethal progression in men treated for localized prostate cancer: Development and validation studies. Prostate, 2019, 79, 1589-1596.	2.3	8
23	Identifying Genetic Risk Factors for Diabetic Macular Edema and the Response to Treatment. Journal of Diabetes Research, 2020, 2020, 1-12.	2.3	8
24	Genome-wide linkage analyses of hereditary prostate cancer families with colon cancer provide further evidence for a susceptibility locus on 15q11â€“q14. European Journal of Human Genetics, 2010, 18, 1141-1147.	2.8	7
25	Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1619-1624.	2.5	7
26	Identifying Genetic Biomarkers Predicting Response to Anti-Vascular Endothelial Growth Factor Injections in Diabetic Macular Edema. International Journal of Molecular Sciences, 2022, 23, 4042.	4.1	5
27	Urbanâ€“rural prostate cancer disparities in a regional state of Australia. Scientific Reports, 2022, 12, 3022.	3.3	4
28	Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice. BMJ Open Ophthalmology, 2021, 6, e000749.	1.6	3
29	Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C. European Journal of Cancer, 2021, 159, 52-55.	2.8	3
30	Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition. Prostate, 2022, 82, 540-550.	2.3	3
31	The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus. BMC Ophthalmology, 2022, 22, 94.	1.4	2